Article Sidebar

Published
April 28, 2024
Download
PDF
Statistic
Read Counter : 334 Download : 353

Main Article Content

Abstract

Background:
With a 5%–10% global incidence rate, polycystic ovarian syndrome (PCOS) is one of the
most prevalent endocrinal illnesses affecting premenopausal women. Understanding the
pathophysiology of the condition and how to treat it by inhibiting or controlling
associated pathways may need research into the inflammatory processes and mediators
that contribute to the onset and progression of PCOS.
Aim of study:
The current study aims to determine the relationship between serum levels of resistin and
adiponectin and metabolic alterations in PCO patients.
Methods:
Fasting blood samples were collected from 100 PCO married infertile women
(23.30±4.66 years) attending Bint AL-Hoda and Al-Shatra hospitals in Thi- Qar province
- Iraq, in addition to 50 healthy age matched (23.84±4.80 years) control.
According to BMI and fasting serum glucose level, the patients of PCO were classified
into four groups: normal weight nondiabetic patients, normal weight diabetic patients,
overweight non-diabetic patients and overweight diabetic patients compared with
healthy control.
Results:
Adiponectin considerably decreased in all PCO subgroups compared to healthy controls,
but resistin significantly rose in all PCO patients. However, its level was more
substantially (P˂0.05) elevated in overweight diabetics. All PCOS patients had
significantly higher levels of triglycerides, total cholesterol, LDL, and VLDL as
compared to healthy controls. While HDL was not significantly changed in all subgroups
of PCO patients except it significantly declined in overweight diabetic PCO patients.
Conclusion:
PCOS patients had dramatically changed adiponectin, or resistin levels compared to
healthy women. PCOS patients showed low adiponectin levels and high serum resistin
levels, indicating that the pathophysiology of PCOS may be influenced by serum
adiponectin levels. However, in PCOS patients, resistin levels had a separate relationship
with insulin resistance and BMI.

Keywords

Polycystic ovary Resistin Adiponectin

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. - lexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major
  2. unrecognized cardiovascular risk factor in women. Rev Cardiovasc Med 2009;10(2):83-
  3. - Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J
  4. Clin Endocrinol Metab 1961;21:1440-1447.
  5. - Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, et al. Consensus on women's
  6. health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRMSponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97(1):28-38.e25.
  7. - Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, et al. Androgen Excess
  8. Society. Positions statement: criteria for defining polycystic ovary syndrome as a
  9. predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin
  10. Endocrinol Metab 2006;91(11):4237-4245.
  11. - Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition
  12. with psychological, reproductive and metabolic manifestations that impacts on health
  13. across the lifespan. BMC Med 2010;8:41.
  14. - Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary
  15. syndrome revisited: an update on mechanisms and implications. Endocr Rev
  16. ;33(6):981-1030.
  17. - Randeva HS, Tan BK, Weickert MO, Lois K, et al. Cardiometabolic aspects of
  18. the polycystic ovary syndrome. Endocr Rev 2012;33(5):812-841.
  19. - Carmina E, Bucchieri S, Esposito A, Del Puente A, et al. Abdominal fat quantity
  20. and distribution in women with polycystic ovary syndrome and extent of its relation to
  21. insulin resistance. J Clin Endocrinol Metab 2007;92(7):2500-2505.
  22. - Hotta K, Funahashi T, Arita Y, Takahashi M, et al. Plasma concentrations of a
  23. novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler
  24. Thromb Vasc Biol 2000;20(6):1595-1599.
  25. - Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, et al. Adiponectin: a key
  26. adipocytokine in metabolic syndrome. Clin Sci (Lond). 2006;110(3):267-278.
  27. - Ouchi N, Kihara S, Arita Y, Maeda K, et al. Novel modulator for endothelial
  28. adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation
  29. ;100(25):2473-2476.
  30. - Ardawi MS, Rouzi AA. Plasma adiponectin and insulin resistance in women with
  31. polycystic ovary syndrome. Fertil Steril 2005;83(6):1708-1716.
  32. - Carmina E, Orio F, Palomba S, Cascella T, et al. Evidence for altered adipocyte
  33. function in polycystic ovary syndrome. Eur J Endocrinol 2005;152(3):389-394.
  34. - Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management
  35. of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome.
  36. Hormones (Athens) 2017;16(4):373-380.
  37. - Lazaridou S, Dinas K, Tziomalos K. Prevalence, pathogenesis and management
  38. of prediabetes and type 2 diabetes mellitus in patients with polycystic ovary syndrome.
  39. Hormones (Athens) 2017;16(4):373-380.
  40. - Weyer C, Funahashi T, Tanaka S, Hotta K, et al. Hypoadiponectinemia in obesity
  41. and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin
  42. Endocrinol Metab 2001;86(5):1930-1935.
  43. - Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, et al.
  44. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study.
  45. Hum Reprod 2006;21(9):2257-65.
  46. - Nishizawa H, Shimomura I, Kishida K, Maeda N, et al. Androgens decrease
  47. plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes
  48. ;51(9):2734-2741.
  49. - Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin
  50. concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002;87(6):2764-
  51. - Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and
  52. associated comorbidities? J Mol Med (Berl) 2002;80(11):696-702.
  53. - Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance.
  54. Trends Endocrinol Metab. 2002;13(1):18-23.
  55. - Steppan CM, Bailey ST, Bhat S, Brown EJ, et al. The hormone resistin links
  56. obesity to diabetes. Nature 2001;409(6818):307-312.
  57. - Panidis D, Koliakos G, Kourtis A, Farmakiotis D, et al. Serum resistin levels in
  58. women with polycystic ovary syndrome. Fertil Steril 2004;81(2):361-366.
  59. - Xita N, Georgiou I, Tsatsoulis A, Kourtis A, et al. A polymorphism in the resistin
  60. gene promoter is associated with body mass index in women with polycystic ovary
  61. syndrome. Fertil Steril 2004 N;82(5):1466-1467.
  62. - Seow KM, Juan CC, Wu LY, Hsu YP, et al. Serum and adipocyte resistin in
  63. polycystic ovary syndrome with insulin resistance. Hum Reprod 2004;19(1):48-53.
  64. - Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific
  65. secretory factor inhibits adipocyte differentiation. J Biol Chem 2001;276(14):11252-
  66. - Carmina E, Orio F, Palomba S, Longo RA, et al. Endothelial dysfunction in
  67. PCOS: role of obesity and adipose hormones. Am J Med 2006;119(4):356.
  68. - Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP.
  69. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab
  70. ;18(7):280-285.
  71. - Wild RA, Painter PC, Coulson PB, Carruth KB, et al. Lipoprotein lipid
  72. concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin
  73. Endocrinol Metab 1985;61(5):946-951.
  74. - Wild RA, Painter PC, Coulson PB, Carruth KB, et al. Lipoprotein lipid
  75. concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin
  76. Endocrinol Metab 1985;61(5):946-951.
  77. - Bik W, Baranowska-Bik A, Wolinska-Witort E, Chmielowska M, et al. The
  78. relationship between metabolic status and levels of adiponectin and ghrelin in lean
  79. women with polycystic ovary syndrome. Gynecol Endocrinol 2007;23(6):325-31.
  80. - Komatsu M, Ohfusa H, Aizawa T, Hashizume K. Adiponectin inversely correlates
  81. with high sensitive C-reactive protein and triglycerides, but not with insulin sensitivity, in
  82. apparently healthy Japanese men. Endocr J 2007;54(4):553-558.
  83. - Koh KK, Quon MJ, Han SH, Lee Y, et al. Simvastatin improves flow-mediated
  84. dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic
  85. patients. Diabetes Care 2008;31(4):776-782

Similar Articles

You may also start an advanced similarity search for this article.